Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (KURA)
NASDAQ:KURA
KURA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.79 - $23.48
Previous CloseN/A
Volume631.17K
Average Volume (3M)1.22M
Market Cap
$633.12M
Enterprise Value$1.26B
Total Cash (Recent Filing)$41.51M
Total Debt (Recent Filing)$16.97M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
May 01, 2025EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding80,754,960
10 Day Avg. Volume1,311,384
30 Day Avg. Volume1,222,990
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.75
Price to Cash Flow (P/CF)0.60
P/FCF Ratio0.60
Enterprise Value/Market Cap1.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit23.39
Enterprise Value/Ebitda-7.19
Forecast
1Y Price Target
$26.25Price Target Upside234.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
---
Kura Oncology News
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe zifto franchise is fully funded in 1L, suggesting financial stability and capacity for continued development.
Investment OpportunityKura shares are considered an attractive investment opportunity, given the recent weakness in share price and a significant cash position.
Regulatory ProgressKura obtained regulatory alignment for the KOMET-017 pivotal trials, which evaluate ziftomenib in combination with other treatments for AML, showing regulatory progress.
Bears Say
Market CautionAnalysts remain cautious heading into the KOMET-001 data at ASCO.
Operating CostsR&D expenses were higher than both the analyst's and consensus estimates, indicating increased operating costs.
---
Ownership Overview
1.47% Insiders
11.16% Mutual Funds
1.52% Other Institutional Investors
71.98% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KURA FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was $6.79 and its highest was $23.48 in the past 12 months.
What is Kura Oncology’s market cap?
Kura Oncology’s market cap is $633.12M.
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is May 01, 2025 which is in 37 days.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on Feb 26, 2025. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.636 by $0.416.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -0.62.
How many shares outstanding does Kura Oncology have?
Kura Oncology has 80,754,960 shares outstanding.
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.636. Following the earnings report the stock price went down -1.544%.
Which hedge fund is a major shareholder of Kura Oncology?
Currently, no hedge funds are holding shares in KURA
---
Kura Oncology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.25 (234.82% Upside)
$26.25 (234.82% Upside)
Blogger Sentiment
Bullish
KURA Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 845.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $179.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.27%
12-Months-Change
Fundamentals
Return on Equity
-42.91%
Trailing 12-Months
Asset Growth
131.81%
Trailing 12-Months
Company Description
Kura Oncology
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.
---
KURA Company Deck
---
KURA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment, driven by significant advancements in clinical trials, regulatory progress, and a strong financial position, despite increased expenses and ongoing net losses.Read More>---
KURA Stock 12 Month Forecast
Average Price Target
$26.25
▲(234.82% Upside)
Technical Analysis
Best Analysts Covering KURA
1 Year
1 Year Success Rate
17/43 ratings generated profit
1 Year Average Return
+18.08%
reiterated a buy rating 3 months ago
Copying Leah R. Cann's trades and holding each position for 1 Year would result in 39.53% of your transactions generating a profit, with an average return of +18.08% per trade.
---